RxDoctor Payments Data

Sherry Castillo, MD

Family Medicine · Medford, ORNPI 1689799405

Payments from drug & device makers

$847in general payments, 2019–2025

Across 25 payments — averaging $33.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Tactile Systems Technology Inc$228
  • Therapeuticsmd, Inc.$140
  • W. L. Gore & Associates, Inc.$106
  • Lilly USA, LLC$93
  • Astellas Pharma US Inc$53
  • Pfizer$48
  • plus $180 from 8 others

What the payments were for

  • Food & beverage$847100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$847 in reported general payments places this provider in the 85th percentile of 1,221 family medicine providers in Oregon.

See all family medicine providers in Oregon

Medicare billing

Part B allowed, 2024
$50,478
Medicare patients
138
Services billed
655

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin37$47,583
MounjaroTirzepatide35$39,971
EliquisApixaban39$37,414
OzempicSemaglutide18$32,926
FarxigaDapagliflozin Propanediol13$19,065
XareltoRivaroxaban12$12,344
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$12,311
Repatha SureclickEvolocumab16$8,867
MyrbetriqMirabegron11$6,665
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr13$6,538
ZenpepLipase/Protease/Amylase12$6,117
SynthroidLevothyroxine Sodium40$2,032
Estradiol45$1,935
Levothyroxine Sodium161$1,645
Gabapentin102$1,635

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Olanzapine$93$40,74757 claims
PfizerEliquis$48$37,41439 claims
Novo NordiskOzempic$25$32,92618 claims
AstraZenecaFarxiga$16$19,06513 claims
Johnson & JohnsonXarelto$30$12,34412 claims
Astellas Pharma US IncMyrbetriq$53$6,66511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,221 family medicine providers in Oregon.

Other family medicine in Medford

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →